Drug Target Insights is an international, peer-reviewed, open access journal, covering current developments in all areas of the field of clinical therapeutics and focusing on molecular drug targets which include disease-specific proteins, receptors, enzymes, and genes. The journal seeks to elucidate the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life. The journal welcomes unsolicited article proposals. All articles are listed on PubMed and are freely available via PubMed Central.
This journal is a member of the Committee on Publication Ethics (COPE).
Please visit the journal’s homepage for more information, to access full text content, and/or to submit a manuscript.
Abstracting and Indexing
Article Processing Charges (APCs)*
There is no charge for submitting a paper to Drug Target Insights. Upon acceptance of your manuscript, you will be charged a one-time article processing charge (APC) of 1,848 USD. This fee covers the cost of publication and ensures that your article will be freely available.
Benefits of Publishing
The journal offers significant benefits to authors including:
- International, peer-reviewed open access journal
- Listed on PubMed and freely available via PubMed Central
- Indexed in: Web of Science Emerging Sources Citation Index (ESCI), Directory of Open Access Journals (DOAJ) and Scopus
- Fast, rigorous peer review
- Open access format, driving high visibility and global exposure
- Article metrics service to allow each author to monitor re-use of published articles
* The article processing charge (APC) is payable when the manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.
Drug Target Insights is an international, open access, peer-reviewed journal, covering current developments in all areas of the field of clinical therapeutics and focusing on molecular drug targets which include disease-specific proteins, receptors, enzymes, and genes.
The journal seeks to elucidate the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life. The journal welcomes a wide range of article types, including original research, methodologies, case reports, reviews, perspectives, editorials and commentaries.
Original research manuscripts may include in vitro and translational studies as well as all phases of animal or human/clinical studies. All articles are listed on PubMed and are freely available via PubMed Central.
|Anuj Chauhan||Chemical and Biological Engineering, Colorado School of Mines, Colorado, USA|
|Julie Andrews PhD||University of Manchester, Manchester, UK|
|Marianna K.Baum PhD||Robert Stempel College of Public Health and Social Work, Florida International University, Miami, Florida, USA|
|Xiuping Chen PhD||Institute of Chinese Medical Sciences, University of Macau, Macau, China|
|Karine Cohen-Solal PhD||Cancer Institute of New Jersey, New Brunswick, New Jersey, USA|
|Andrew Coop PhD||University of Maryland, Baltimore County, Baltimore, Maryland, USA|
|Gautam Damera PhD||Translational Medicine Medimmune LLC, Gaithersburg, Maryland, USA|
|Giovanna Lucia Maria Damia PhD||Mario Negri Instituto di Ricerche Farmacologiche, Milan, Italy|
|Laurence Fitzhenry PhD||Waterford Institute of Technology, Waterford, Ireland|
|Anna Koumarianou MD PhD||Attikon University General Hospital, National Kapodistrian University of Athens, Medical School, Athens, Greece|
|Salvatore D. Lepore PhD||Florida Atlantic University, Boca Raton, Florida, USA|
|Dale G. Nagle PhD||Research Institute of Pharmaceutical Sciences (RIPS), School of Pharmacy, University of Mississippi University, Mississippi, USA|
|Marko Radic PhD||University of Tennessee Health Science Center, Memphis, Tennessee, USA|
|John N. van den Anker PhD||Children's National Medical Center, Children's Research Institute, Washington DC, USA|
|Raja Solomon Viswas PhD||Nagoya City University, Graduate School of Pharmaceutical Sciences, Mizuho-ku, Nagoya, Aichi, Japan|
Drug Target Insights Manuscript Submission Guidelines
Table of Contents:
1. Open Access
2. Article processing charge (APC)
3. What do we publish?
3.1 Aims & Scope
3.3 Writing your paper
4. Editorial policies
4.1 Peer review policy
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical trials
4.8 Reporting guidelines
5. Publishing policies
5.1 Publication ethics
5.2 Contributor’s publishing agreement
6. Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplementary material
6.4 Reference style
6.5 English language editing services
7. Submitting your manuscript
7.1 How to submit your manuscript
7.2 Title, keywords and abstracts
7.3 Information required for completing your submission
8. On acceptance and publication
8.1 SAGE Production
8.2 Online publication
8.3 Promoting your article
9. Further information
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site http://peerreview.sagepub.com/DTI to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.
Only manuscripts of sufficient quality that meet the aims and scope of Drug Target Insights will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Drug Target Insights may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy.
If your paper is accepted, you must include a link on your preprint to the final version of your paper.
Drug Target Insights is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
The APC for this journal is currently 1848 USD.
Before submitting your manuscript to Drug Target Insights, please ensure you have read the Aims & Scope.
1. Original Articles. The Editors will consider preclinical, interventional and observational studies with clearly stated aims, well-reported methodology (including main outcome measures) and results, and a discussion of the results in the context of the published literature).
2. Review Articles. The following types of high-quality review will be considered: (a) General reviews that provide a synthesis of an area that fits within the aims and scope of the journal; (b) Drug reviews – review articles focusing on the available evidence for the use of a particular drug or combination therapy.
3. Perspective Reviews. Review-style articles that address important new areas of general interest and afford the author the opportunity to present a forward-looking perspective on the topic and/or incorporate their own experience in the field;
4. Systematic Reviews. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8).
5. Meta-analyses. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8).
6. Case Reports. These structured reports should describe an unusual case and include a full review of the pertinent literature and a section on implications for clinical care.
7. Study Protocols. These can be for forthcoming or ongoing research. Information on trial registration (where applicable) and ethics approval should be included in the manuscript.
8. Editorials. Editorials are short articles on topics of recent interest that discuss the findings, implications, and/or outcomes of specific research or wider research on a general topic. These articles are usually commissioned by the Editor.
9. Opinion. Similar to Editorials, these short articles address a topic under debate, and provide the opportunity for the author to voice their opinion on a particular study or area of research. These articles are usually commissioned by the Editor.
10. Letters to the Editor. These brief pieces should be as concise as possible, usually no more than 1000 words.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
3.3.1 Making your article discoverable
For information and guidance on how to make your article more discoverable, visit our Gateway page on How to Help Readers Find Your Article Online
Following a preliminary triage to eliminate submissions unsuitable for Drug Target Insights all papers are sent out for review. The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication. If your paper should be considered for fast-track publication, please explain why.
The journal’s policy is to have manuscripts reviewed by at least two expert reviewers. Drug Target Insights utilizes a single-blind peer review process in which the reviewer’s name and information is withheld from the author All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editor-in-Chief who then makes the final decision.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor / Board member will have no involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors. The list of authors should include all those who can legitimately claim authorship. This is all those who:
(i) Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
(ii) Drafted the article or revised it critically for important intellectual content,
(iii) Approved the version to be published,
(iv) Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Drug Target Insights requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Drug Target Insights encourages authors to include a declaration of any conflicting interests and recommends you review the good practice guidelines on the SAGE Journal Author Gateway.
It is the policy of Drug Target Insights to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors
Drug Target Insights conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
Drug Target Insights and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Drug Target Insights publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines
Figures supplied in color will appear in color online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article. For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.
Drug Target Insights adheres to the AMA Manual of Style. View the guide here to ensure your manuscript conforms to this style.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximize your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Drug Target Insights editorial office as follows:
Neisha Jobanputra, email@example.com